Events

Transforming Biopharmaceutical Research with AI at The HESI Annual Meeting 2020.

TUESDAY 9 JUNE | VIRTUAL EVENT

Abstract

The Health and Environmental Sciences Institute (HESI)’s mission is to develop science for a safer, more sustainable world. For HESI’s Annual Meeting 2020, our Executive board director, Jackie Hunter, will take to the virtual stage to demonstrate how AI can be used right at the beginning of the R&D process to improve target identification and validation as well as being used to identify key pathways in disease. Benevolent’s technology platform can be used to better predict the properties of molecules including their safety leading to fewer compounds needing to be physically made. There are still considerable challenges in applying the technology – primarily around access to data, especially negative data and these will be discussed.

 

Prof. Jackie Hunter, BenevolentAI

Professor Jackie Hunter held senior positions at global pharmaceutical organisations including GSK, Proximagen and OI Pharma Partners before joining BenevolentAI as an Executive Board Director in 2016. She brings vast academic and business experience in the biomedical and pharmaceutical sectors. For her services to the pharmaceutical industry, she was awarded a CBE in 2010, Birthday Honours and the 2010 Women of Achievement in Science, Engineering and Technology Award for Discovery, Innovation and Entrepreneurship. She gives the company the insight it needs to operate its unique business model – one which sees it not only researching, but also developing the blueprint for new drugs.

REGISTER >

More Posts

You Might Also Like

News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021
News
BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020
BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.
Mar 8, 2021
Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021